New molecular targets in cancer therapy. Do they have palliative function?;Nuevas dianas moleculares en la tarapia del cáncer. ¿Tienen función paliativa?

Medicina Paliativa

Volumn 10, Issue 4, 2003, Pages 220-225

  Sanz Ortiz, Jaimen ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Epithelial growth factor receptor; New molecular targets; Receptor tyrosine kinase; Symptom control

Indexed keywords

ANALGESIC AGENT; ANOREXIGENIC AGENT; ANTINEOPLASTIC AGENT; ANXIOLYTIC AGENT; CETUXIMAB; CISPLATIN; CYTOSTATIC AGENT; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; INTERFERON; MEMBRANE RECEPTOR; OPIATE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

ACNE; ADVANCED CANCER; ALOPECIA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOPLASM; CYTOSTASIS; CYTOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; EPITHELIUM; EXTRACELLULAR SPACE; FUNCTIONAL ASSESSMENT; HISTORY; HUMAN; INTRACELLULAR SPACE; LEIOMYOSARCOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; NAUSEA; NEUROPATHY; ONCOLOGY; PERFORMANCE; PHASE 3 CLINICAL TRIAL; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TERMINAL DISEASE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0346732255     PISSN: 1134248X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 20.00: Cancer Incidence, Mortality and Prevalence Word Wide. Version 1.0. IARC CancerBase N. 5.Lyon IARC Press, 2001. Limited version available from http://www-dep.iarc.fr/globocan.html.
2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 (Supl. 8): S4-S66.
3. Natale RB, Zaretsky SL. ZD1839 (Iressa™): What's in it for the patient? The Oncologist 2002; 7 (Supl. 4): 25-30.
4. Sanz Ortiz J, Rivera Herrero F, Juan Ferré A, Vega Villegas ME. Tratamiento oncológico activo de la enfermedad neoplásica avanzada y terminal. Med Clin (Barc) 2000; 114: 302-7.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
6. Baselga J. Why the Epidermal Growth Factor Receptor? The rationale for cancer therapy. The Oncologist 2002; 7: (Supl. 4): 2-8.
7. Yarden Y, Sliwkowski MX. Untangling the EcrbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
8. Raymond E, Faire S, Armand JP. Epidermal growth factor receptor tyrosine kinase as target for anticancer therapy. Drugs 2000; 60 (Supl. 1): 15-23.
9. Slichenmeyer WJ, Fray DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinase. Semin Oncol 2001; 28 (Supl. 16): 67-79.
10. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogen 2000; 19: 6550-65.
11. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with non-small cell lung cancer: descriptive study based scripted interviews. BMJ 1998; 317: 771-5.
12. Lutz S, Norrell R, Bertucio C, Kachnic L, Johnson C, Arthur D, et al. Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung Cancer Symptom Scale in a community hospital. J Palliat Med 2001; 4: 157-65.
13. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using update data on individual patients from 52 ramdomised clinical trials. BMJ 1995; 311: 899-909.
14. Couillard J-Y, Giaccone G, Horai T, et al. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSLC) treated with ZD1839 (Iressa®) (IDEAL 1) Oric Am Soc Clin Oncol 2002; 21: 299a (A1195).
15. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Final results from a Phase II trial of ZD1839 (Iressa) for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002; 21: 292a (A1167).
16. Natale RB, Skarin AT, Maddox A-M, Hammond LA, Thomas R, Gandara DR, et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer (NSCLC) patients receiving ZD1839 (Iressa) in IDEAL 2. Proc Am Soc Clin Oncol 2002; 21: 292a (A167).
17. Kris MG, Natale RB, Herbst RS, et al. A Phase II of Zd1839 (Iressa) in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002; 21: 292a (A116).
18. Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002; 55: 285-95.
19. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 2001; 31: 233-40.
20. Degner LF, Sloan JA. Symptom distress in newly diagnoses ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manage 1995; 10: 423-31.
21. Ibidem 20
22. Ob. cit. 2
23. Ries L, Eisner MP, Korsay CL. SEER Cancer Statistics Review, 1973-1998. Bethesda, MD: National Cancer Institute, 2001.
24. Soni MK, Cella D, Masters AG, Burch, Heyes A, Silberman CH. The validity and clinical utility of symptom monitoring in advanced lung cancer: a literature review. Clin Lung Cancer 2002; 4: 153-60.
25. Lutz S, Norrel R, Bertuccio C, Kachnic L, Johnson C, Arthur D, et al. Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung cancer Symptom Scale in a common hospital. J Palliat Med 2001; 4: 157-65.